# A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

> **NCT00541749** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** rhuMAb IFNalpha

## Key facts

- **NCT ID:** NCT00541749
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541749, "A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00541749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*